NEW YORK and HAIKOU, China, May 16 /Xinhua-PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it donated 2 million RMB (approximately US$285,714) worth of its products including antibiotics, anti-virus and anti-cold medicines to help disaster relief in China after a strong earthquake hit the southwestern province of Sichuan.
On May 12, a 7.9-magnitude quake struck in Wen Chuan， Sichuan province，China and toppled schools, apartment buildings and factories. Thousands of people were killed or trapped in mounds of concrete, steel and earth in the country's worst quake in three decades. China Pharma quickly reacted to the tragedy and made a donation of medicines to the earthquake-hit areas starving for help. Meanwhile, every employee of China Pharma is actively making donations for the survivors of this devastating earthquake in Sichuan.
"I am extremely shocked and saddened by the extent of the destruction caused by this earthquake in Sichuan Province. Our company and our employees feel a profound sympathy for the people suffering from this terrible tragedy at this time, and we are offering our support to these people and their families and sincerely hope that they could rebuild their homes in the near future," Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc. said.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
